RxDoctor Payments Data

John Byrd

Internal Medicine · Graceville, FLNPI 1073932828

Payments from drug & device makers

$2,305in general payments, 2019–2025

Across 136 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$608
  • AstraZeneca$436
  • Novo Nordisk$272
  • GSK$198
  • Merck$148
  • Amgen$136
  • plus $508 from 9 others

What the payments were for

  • Food & beverage$2,22597%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,305 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$17,317
Medicare patients
74
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol187$149,830
OzempicSemaglutide115$139,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$91,153
MounjaroTirzepatide78$86,624
EliquisApixaban77$73,335
GlyxambiEmpagliflozin/Linagliptin60$57,153
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog39$37,534
MyrbetriqMirabegron57$35,019
Tresiba Flextouch U-200Insulin Degludec21$34,289
TrulicityDulaglutide22$31,710
Janumet XrSitagliptin Phos/Metformin Hcl35$28,623
XareltoRivaroxaban22$25,827
JanuviaSitagliptin Phosphate18$21,380
JardianceEmpagliflozin25$18,666
RybelsusSemaglutide15$15,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$272$155,377130 claims
AstraZenecaFarxiga, Bevespi Aerosphere$436$154,596198 claims
Lilly USA, LLCMounjaro, Trulicity$608$118,334100 claims
GSKTrelegy Ellipta, Shingrix$198$94,769124 claims
MerckJanumet Xr, Januvia$148$50,00353 claims
Astellas Pharma US IncMyrbetriq$80$35,01957 claims
Johnson & JohnsonXarelto$88$25,82722 claims
AbbVieNamzaric$126$7,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Graceville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →